An impact on prognosis emerged when we focused on genetically undefined patients, that means with intermediate-risk or lack of growth karyotype, and triple-negative for NPM1, FLT3-ITD and CEBPA (TN-AML). The gene discussed is FLT3; the disease is acute myeloid leukemia.